Barclays’s Apogee Therapeutics APGE Stock Holding History

Barclays’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-20,031	Closed	-$2.66M	–	5386
2026 Q2	$2.66M	Sell	20,031 -30,365	-60%	-$2.74M	﹤0.01%	2200
2026 Q1	$4.24M	Sell	50,396 -82,797	-62%	-$6.01M	﹤0.01%	1920
2025 Q4	$10.1M	Sell	133,193 -509,123	-79%	-$32.1M	﹤0.01%	1668
2025 Q3	$25.5M	Buy	642,316 +33,494	+6%	+$1.28M	0.01%	1089
2025 Q2	$26.4M	Buy	608,822 +110,197	+22%	+$4.19M	0.01%	977
2025 Q1	$18.6M	Buy	498,625 +21,865	+5%	+$845K	0.01%	1073
2024 Q4	$21.6M	Buy	476,760 +111,714	+31%	+$5.7M	0.01%	1078
2024 Q3	$21.4M	Buy	365,046 +287,243	+369%	+$13.8M	0.01%	1033
2024 Q2	$3.06M	Buy	77,803 +41,157	+112%	+$2M	﹤0.01%	1845
2024 Q1	$2.44M	Buy	36,646 +2,590	+8%	+$113K	﹤0.01%	2410
2023 Q4	$952K	Buy	+34,056	New	+$683K	﹤0.01%	3466

Other funds holding APGE

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Barclays's APGE Position: Q3 2026 in Review

Barclays sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 20,031 shares — an estimated $2.66M sold.

Barclays first reported a position in APGE in Q4 2023 and held it in 11 quarters. The position peaked at $26.4M in Q2 2025. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

Barclays reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
Barclays sold 20,031 Apogee Therapeutics shares in Q3 2026, an estimated $2.66M.
Barclays first reported a position in Apogee Therapeutics in Q4 2023 and held it in 11 quarters.
Barclays's Apogee Therapeutics position peaked at $26.4M in Q2 2025.
2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.